These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
925 related articles for article (PubMed ID: 32212178)
1. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Rajkumar SV Am J Hematol; 2020 May; 95(5):548-567. PubMed ID: 32212178 [TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Rajkumar SV Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063 [TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Rajkumar SV Am J Hematol; 2024 Sep; 99(9):1802-1824. PubMed ID: 38943315 [TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Rajkumar SV Am J Hematol; 2016 Jul; 91(7):719-34. PubMed ID: 27291302 [TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Rajkumar SV Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663 [TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Vincent Rajkumar S Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428 [TBL] [Abstract][Full Text] [Related]
7. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268 [TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Rajkumar SV Am J Hematol; 2011 Jan; 86(1):57-65. PubMed ID: 21181954 [TBL] [Abstract][Full Text] [Related]
9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Rajkumar SV Am J Hematol; 2012 Jan; 87(1):78-88. PubMed ID: 22180161 [TBL] [Abstract][Full Text] [Related]
11. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870 [TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155 [TBL] [Abstract][Full Text] [Related]
15. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P Future Oncol; 2024; 20(38):3043-3063. PubMed ID: 39287147 [TBL] [Abstract][Full Text] [Related]
16. Current approaches to management of newly diagnosed multiple myeloma. Goel U; Usmani S; Kumar S Am J Hematol; 2022 May; 97 Suppl 1():S3-S25. PubMed ID: 35234302 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience. Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321 [TBL] [Abstract][Full Text] [Related]